Delving into the Latest Updates on Beijing Dezhong Wanquan Medicine Technology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Opioid receptors	1

以24名健康男性志愿者为试验对象，采用自身交叉对照的试验设计，考察美吉斯制药（厦门）有限公司研制的雷奈酸锶颗粒与法国施维雅药厂生产的雷奈酸锶干混悬剂的相关药代动力学参数及相对生物利用度，评价两制剂的生物等效性，为美吉斯制药（厦门）有限公司研制的雷奈酸锶颗粒的临床应用提供依据。

[Translation]

A self-crossover design was adopted with 24 healthy male volunteers as the test subjects to investigate the pharmacokinetic parameters and relative bioavailability of strontium ranelate granules developed by Magis Pharmaceuticals (Xiamen) Co., Ltd. and strontium ranelate dry suspension produced by Servier Pharmaceuticals in France, and to evaluate the bioequivalence of the two preparations, so as to provide a basis for the clinical application of strontium ranelate granules developed by Magis Pharmaceuticals (Xiamen) Co., Ltd.

Start Date-

Sponsor / Collaborator

Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

CTR20150239 / Not yet recruitingPhase 1

盐酸洛哌丁胺口崩片人体生物等效性试验

[Translation] Bioequivalence study of loperamide hydrochloride orodisintegrating tablets in human subjects

采用自身交叉对照的试验设计，考察美吉斯制药（厦门）有限公司研制的盐酸洛哌丁胺口腔崩解片与西安杨森制药有限公司生产的盐酸洛哌丁胺胶囊的相关药代动力学参数及相对生物利用度，评价两制剂的生物等效性，为美吉斯制药（厦门）有限公司研制的盐酸洛哌丁胺口腔崩解片的临床应用提供依据。

[Translation]

A self-crossover experimental design was used to investigate the relevant pharmacokinetic parameters and relative bioavailability of loperamide hydrochloride orally disintegrating tablets developed by Magis Pharmaceuticals (Xiamen) Co., Ltd. and loperamide hydrochloride capsules produced by Xi'an Janssen Pharmaceuticals Co., Ltd., and to evaluate the bioequivalence of the two preparations, so as to provide a basis for the clinical application of loperamide hydrochloride orally disintegrating tablets developed by Magis Pharmaceuticals (Xiamen) Co., Ltd.

Start Date-

Sponsor / Collaborator

Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

100 Clinical Results associated with Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

01 Jan 2019·Drug DeliveryQ2 · MEDICINE

Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells

Q2 · MEDICINE

ArticleOA

Author: Sun, Mingshuang ; Han, Cuiyan ; Fan, Li ; Zhou, Jianwen ; Sui, Xiaoyu ; Jin, Shanshan ; Yang, Chunrong ; Zhu, Wenquan ; Cao, Lixin

The existing of avidity cancer stem cells (CSCs) made it an optical strategy to kill cancer cells and CSCs at the same time. Here, we constructed a CSCs specific nanocarrier naming T-S-NLC using the CD133+ targeting peptide TISWPPR (TR) as the targeting moiety attached to the distal end of PEG on salinomycin (Sal) loaded nanostructured lipid carriers (NLC), its pharmaceutical characteristics proved it 128.73 ± 2.09 nm, anionic spheroid with sustained release profile. It's in vitro targeting effect in CD133+ CSCs indicated that it exhibited superior CSCs internalization over non-modified NLC or free drug. Afterwards, it was used in combination with previously designed EGFR specific A-P-NLC (AEYLR peptide-PEG-modified paclitaxel loaded NLC) to achieve the goal to kill the cancer cells and CSCs, simultaneously. The in vitro tumor targeting effect of T-S-NLC + A-P-NLC was affirmed by cellular uptake and proliferation inhibition effect in NCI-H1299 and S180 cell lines showing advanced results over single preparation groups. In vivo tumor targeting effect in S180 tumor-bearing mice also validated the better tumor accumulative effect of the combined group. Last but not least, the in vivo antitumor effect strongly identified the greater tumor suppression effect of T-S-NLC + A-P-NLC than single preparation groups or combined use of free drugs while maintaining a good living state of the mice. To sum up, the combined usage of PTX and Sal active targeting NLC naming A-P-NLC + T-S-NLC which killed cancer cells and CSCs at the same time was a promising drug delivery system.

100 Deals associated with Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Dezhong Wanquan Medicine Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data